| |
Orexigen Therapeutics, Inc. (OREX)
|
| Last Traded At: |
$6.49
-
($0.01)
|
| Volume: |
65,081 |
| Price/Earnings: |
$0.00 |
| Earnings Per Share: |
($2.05) |
| 52 Week High: |
$10.83 |
| 52 Week Low: |
$1.78 |
 |
| StockSpiker Coverage & Performance |
|
This stock has been covered by StockSpiker on the following dates. In addition, the percentage change from the coverage date and today's price is shown.
|
| Coverage |
Coverage
Date |
Gain Since Then |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| About Orexigen Therapeutics, Inc. |
| Orexigentm Therapeutics, Inc. ("Orexigen", "we", "our" and "us") is a
biopharmaceutical company focused on the development of pharmaceutical product
candidates for the treatment of central nervous system, or CNS, disorders,
including obesity. Our lead product candidates targeted for obesity are
Contravetm, which is in Phase III clinical trials, and Empatictm, which is in
the later stages of Phase II clinical development. Each of these product
candidates is a combination of generic drugs, which we have systematically
screened for synergistic CNS activity. We seek to combine chemical entities
that, individually, have already received regulatory approval and have been
commercialized previously, into new product candidates that we believe address
unmet medical needs and are patentable. We are testing these combinations in an
effort to demonstrate adequate efficacy and safety for potential regulatory
approval. |
 |
|
|
|
| News For Orexigen Therapeutics, Inc. |
| 3/9/2010 1:10:35 PM |
Orexigen Therapeutics narrows 4th-quarter loss (AP) |
| 3/9/2010 12:46:29 PM |
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (EDGAR Online) |
| 3/9/2010 12:15:00 PM |
Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results (PR Newswire) |
| 3/5/2010 1:00:00 PM |
Orexigen(R) Therapeutics to Speak at Cowen & Company Healthcare Conference (PR Newswire) |
| 3/5/2010 1:00:00 PM |
Orexigen(R) Therapeutics to Speak at Cowen & Company Healthcare Conference (PR Newswire) |
| 3/4/2010 1:36:00 PM |
Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009 (PR Newswire) |
| 3/4/2010 1:36:00 PM |
Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009 (PR Newswire) |
| 3/2/2010 9:52:35 PM |
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial St (EDGAR Online) |
| 3/2/2010 1:00:00 PM |
Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors (PR Newswire) |
| 3/2/2010 1:00:00 PM |
Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors (PR Newswire) |
|
|
This website is intended to provide information only. If you are seeking advice on any matters relating to information on this website, you should - where appropriate - contact your broker or investment manager directly with your specific questions or seek advice from qualified Professional Financial advisor.
Whether you are a technical daytrader, or a long term fundamental investor, the StockSpiker gives you investment ideas based on the most relevant recent price
history of stocks. Here are some recent movers that we have reported on:
|
| |